Increasing Diversity in Clinical Trials Expert Meeting

Tuesday, October 12 & Thursday, October 21, 2021

1:00 p.m. – 4:00 p.m. EDT

Virtual Event

CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials.

MEETING OBJECTIVES:

- Present findings from project evidence generation: in-depth interviews with key decision-makers.
- Refine a maturity model for organizational-level strategies to increase diversity in clinical trials.
- Identify specific multi-stakeholder, portfolio-level strategies to increase the participation of underrepresented racial and ethnic minorities and women in clinical trials.

TUESDAY, OCTOBER 12

Integrating Diversity into Organizations

1:00 p.m. Welcoming Remarks & Project Overview

Sara Bristol Calvert, CTTI

1:05 p.m. Session I: Evidence Generation Results

Review In-depth Interview Results
Session Facilitator: Amy Corneli, CTTI

1:35 p.m. Q&A and General Discussion

1:55 p.m. Break

2:00 p.m. Session II: Organizational Strategies to Increase Diversity in Clinical Trials

Lessons Learned from the Yale Center for Clinical Investigation
Session Facilitator: Tesheia Johnson, Yale University

Panelists:
Keith Churchwell, Yale New Haven Hospital
Brian Smith, Yale School of Medicine

Q&A and General Discussion

2:55 p.m. Break

3:05 p.m. Session III: Diversity Maturity Model Breakout Discussions

Session Objectives:

- Each group discusses and refines one part of the maturity model.

Breakout Group Discussions:

- Group 1: Scientific Disease Level Strategy
- Group 2: Community & Patient Engagement
- Group 3: Measurement of Impact

3:55 p.m. Introduction of Day 2 & Wrap-Up

Sara Bristol Calvert, CTTI

4:00 p.m. Adjourn Day 1

THURSDAY, OCTOBER 21

Developing Multi-Stakeholder, Portfolio-Level Strategies to Increase Diversity in Clinical Trials

1:00 p.m. Session IV: Welcome & Representation in U.S. Clinical Trials

Session Facilitator: Sara Bristol Calvert, CTTI
Recap of Day 1 and Introduction to Day 2

1:05 p.m. *Representation in U.S. Clinical Trials*
Speakers: RADM Richardae Araojo and Kaveeta Vasisht, U.S. Food and Drug Administration (FDA)

Session Objectives:

- Provide broad overview of representation of racial and ethnic minorities and women in U.S. clinical trials

1:35 p.m. Session V: Review of Maturity Model & Interactive Session on Barriers and Opportunities

Session Facilitator: Sara Bristol Calvert, CTTI
Session Objectives:

- Obtain participant feedback on challenges and areas of opportunity for sponsors, sites, patient advocacy groups, and community organizations to work together to develop strategies to increase diversity in clinical trials.
- Review maturity model including suggestions from Day 1

1:55 p.m. Break

2:05 p.m. Session VI: Diversity Maturity Model Breakout Discussions

Session Objectives: Each group discusses and refines one part of the maturity model.

- Group 1: Linking Social Determinants of Health and Scientific Disease Level Strategy
- Group 2: Community Engagement Infrastructure
- Group 3: What information do different stakeholders need to sustain commitments to, and investments in, operational level strategies?

2:55 p.m. Break

3:05 p.m. Summary of Breakout Groups
Breakout Group Facilitators

3:35 p.m. Closing Comments and Next Steps

3:45 p.m. Adjourn

For more information, contact the Diversity Project Manager, Sara Calvert at sara.calvert@duke.edu, or visit http://www.ctti-clinicaltrials.org